In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

The Value Lab: Moving Value-Based Health Care From Theory To Practice

Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.

BioPharmaceutical Reimbursement Private Payers
Advertisement

Latest From Market Access

Access To Medicines Innovation: Seven Points To A Sustainable System

The Boston Consulting Group convened a roundtable of market access executives from leading biopharma companies in the US, Europe and Japan to reach consensus on how to finance the cost of health care. The group's working paper considers various approaches to financing high-quality care, with an initial emphasis on advocating for change among payers in Europe.

Market Access BioPharmaceutical

New Payment And Financing Models For Curative Regenerative Medicines

Cell and gene therapies that have the potential to cure require new approaches to value assessment, payment and financing. In the second of a series, the Alliance for Regenerative Medicine identifies potential payment models, highlights key stakeholder concerns and identifies the barriers that must be addressed to enable their integration across the health care system.

BioPharmaceutical Pricing Strategies

UK Medtech One Year Post-Brexit Vote: Still In The Land Of Uncertainty

The UK's Brexit and a failed Conservative Party election strategy last month weigh heavily on the minds of local medtech businesses, looking ahead nervously at the type of trade deal the UK might finally strike with the EU. They could be waiting awhile, because the When and What are still not yet apparent – never mind that the Why still rankles with many UK medtechs. That much is clear from a brand new survey of companies, which also reveals the primacy of NHS access.

United Kingdom Brexit

2017 Fair Pricing Forum: The Message For Pharma CEOs

Pharmas were in the minority at WHO's Fair Pricing Forum, but ZS' Ed Schoonveld says that other attendees sent some messages that pharma CEOs should heed.

BioPharmaceutical Market Access

UK General Election Misjudgment: Dismay For May Who Finds The Politics Of Greed Don't Pay

The smart money had increasingly been on a hung parliament in the UK, with the ruling Conservative party being punished for several policy slip-ups, perceived dithering by Prime Minister Theresa May and her insistence on a clean and hard Brexit led by her alone. The June 8 election did not need to be called, and today, May is ruing the fact that she has lost both the party's absolute majority and her mandate to lead on a hard Brexit.

United Kingdom Brexit

EU Medtechs Keep Open Mind On HTA Options In Wider Market Access Plan

Health technology assessment for medtech products in Europe is a strictly national responsibility, but is there a case for an EU-wide HTA system that could improve medtech market access? MedTech Europe chief executive Serge Bernasconi shares his views with In Vivo.

Health Technology Assessment Policy & Regulation
See All
UsernamePublicRestriction

Register